Five Star Equities Issues New Research Reports on CELG, EPZM, LLY and SHW - KMPH FOX 26 | Central San Joaquin Valley News Source

Five Star Equities Issues New Research Reports on CELG, EPZM, LLY and SHW

Posted: Updated:

Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.

Celgene Corporation (NASDAQ: CELG) shares gained 1.22 percent to close at $164.61 a share Tuesday. The stock traded between $164.33 and $166.82 on volume 2.83 million shares traded. The company announced that Abraxane has received European Marketing Authorization as a treatment for pancreatic cancer. Shares of Celgene have gained approximately 100.0 percent in the past year.

Get more information on Celgene free access to the in-depth equity report at:
www.FiveStarEquities.com/CELG

Epizyme Inc. (NASDAQ: EPZM) shares soared 75.56 percent to close at $35.99 a share Tuesday. The stock traded between $31.02 and $37.69 on volume 3.81 million shares traded. The company has announced that it has achieved a proof of concept milestone and has earned a $25.0 million payment from Celgene. Shares of Epizyme have gained approximately 55.0 percent in the past year.

Get more information on Epizyme and free access to the in-depth equity report at:
www.FiveStarEquities.com/EPZM

Eli Lilly & Co. (NYSE: LLY) shares declined 0.66 percent to close at $51.19 a share Tuesday. The stock traded between $51.15 and $52.08 on volume 7.36 million shares traded. The company announced that it expects 2014 revenue to be between $19.2 billion and $19.8 billion and EPS to be in the range of $2.77 to $2.85.

Get more information on Eli Lilly and free access to the in-depth equity report at:
www.FiveStarEquities.com/LLY

Sherwin-Williams Company (NYSE: SHW) shares gained 2.69 percent to close at $187.61 a share Tuesday. The stock traded between $184.57 and $188.17 on volume of 1.24 million shares traded. KeyBanc analyst Ivan Marcuse has upgraded the company’s rating to “buy” from “hold” and has set a price target of $220.0 on the stock. Shares of Sherwin-Williams have gained approximately 18.0 percent in the past year.

Get more information on Sherwin-Williams and free access to the in-depth equity report at:
www.FiveStarEquities.com/SHW

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Five Star Equities
info@fivestarequities.com

Source: http://www.accesswire.com/viewarticle.aspx?id=410811

ReleaseID: 30425

Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and KMPH. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.